Acyclic Lipid Composition for Targeted Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lipid-based delivery systems for nucleic acid and protein therapeutics lack targeted delivery capabilities, failing to localize the cargo to specific cells, tissues, or organs, and do not focus on the lipids used in the delivery system.
Innovation Solution
Development of new lipids with specific structures for delivery vehicles and a tropism discovery platform to screen and develop targeting systems for localized delivery of nucleic acid and protein therapeutics, including cationic, neutral, anionic, and stealth lipids, with a weight ratio of lipids to polynucleotides ranging from 100:1 to 1:1, targeting immune cells such as T cells and macrophages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current lipid-based delivery systems are used, then cargo protection is achieved, but targeted delivery to specific cells, tissues, or organs is not achieved
Solution Approach 1:
The patent applies local quality by modifying specific lipid components within the delivery system to confer targeting properties. The lipid composition is engineered with particular lipids (such as ionizable lipids with specific headgroups or tail structures) that provide localized functionality for cell recognition and uptake, while other lipids maintain structural integrity and cargo protection. This allows different parts of the delivery system to have specialized functions.
Solution Approach 2:
The patent employs composite materials by combining multiple lipid types with distinct properties into a single delivery system. The lipid composition includes ionizable lipids, neutral lipids, and cholesterol derivatives, each contributing different functions such as cargo encapsulation, stability, and targeted delivery. This composite approach enables the system to simultaneously achieve protection and targeting capabilities.
2Stability of the object's composition
If conventional delivery systems focus on cargo protection, then cargo stability is improved, but focus on the lipids used for delivery is lost
Solution Approach 1:
The patent applies parameter changes by systematically optimizing lipid composition parameters including the ratio of ionizable to neutral lipids, cholesterol content, and specific lipid chain lengths. These parameter adjustments are made to balance cargo stability during storage and transport with enhanced cellular uptake and targeting efficiency. The optimized lipid parameters enable improved performance without excessive system complexity.
3Reliability
If targeted delivery to immune cells is achieved, then therapeutic efficacy is improved, but system complexity increases
Solution Approach 1:
The patent uses lipid molecules as intermediaries that mediate between the cargo (nucleic acids or proteins) and the target immune cells. The engineered lipids serve as bridges that facilitate specific interaction with cell surface receptors on immune cells through their tailored chemical structures, enabling targeted delivery without requiring complex external targeting mechanisms.
Data Source
AI summary
The present disclosure details various lipids, compositions, and/or methods of optimized systems and delivery vehicles for the delivery of nucleic acid sequences, polypeptides or peptides for use in vaccinating against infectious agents.